TRIANGLE Study Challenges Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma

Autologous stem-cell transplantation (ASCT) has long been the standard of care for younger patients diagnosed with mantle cell lymphoma, a status established following the publication of the first European Mantle Cell Lymphoma Network trial in 2005. However, this longstanding medical paradigm is now facing significant scrutiny. A recent commentary highlights that the central role of ASCT is being firmly challenged by new findings published in The Lancet. These results stem from the TRIANGLE study, conducted by Martin Dreyling and his colleagues. The study presents evidence that questions the necessity or supremacy of ASCT in current treatment protocols for this specific type of lymphoma. This development marks a potential shift in clinical guidelines and therapeutic strategies for younger patients, suggesting that alternative treatments may offer comparable or superior outcomes. The medical community is now re-evaluating the historical reliance on transplantation as the primary intervention, signaling a possible end to its reign as the undisputed cornerstone of care for mantle cell lymphoma patients.